Quick Answer
International Stem Cell CORP reported Net Income Loss of -$418.0 thousand for the year ending 2025.
- International Stem Cell CORP showed a decrease of -100.0% in Net Income Loss from 2024 to 2025.
- This data is from International Stem Cell CORP's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 20 years of available data (2006 to 2025), International Stem Cell CORP's Net Income Loss has grown by 93.7%.
- Historical annual values: Fiscal year 2025: -$418.0 thousand | Fiscal year 2024: -$209.0 thousand | Fiscal year 2023: -$131.0 thousand | Fiscal year 2022: -$331.0 thousand | Fiscal year 2021: -$899.0 thousand | Fiscal year 2020: -$2.72 million | Fiscal year 2019: -$4.27 million | Fiscal year 2018: -$2.13 million | Fiscal year 2017: -$6.07 million | Fiscal year 2016: -$1.08 million | Fiscal year 2015: -$2.64 million | Fiscal year 2014: -$12.48 million | Fiscal year 2013: -$10.48 million | Fiscal year 2012: -$9.83 million | Fiscal year 2011: -$9.17 million | Fiscal year 2010: -$12.72 million | Fiscal year 2009: -$8.51 million | Fiscal year 2008: -$6.57 million | Fiscal year 2007: -$6.07 million | Fiscal year 2006: -$6.58 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: